Literature DB >> 6580632

Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters.

G L Smith, B R Murphy, B Moss.   

Abstract

A DNA copy of the influenza virus hemagglutinin gene, derived from influenza virus A/Jap/305/57 (H2N2) was inserted into the genome of vaccinia virus under the control of an early vaccinia virus promoter. Tissue culture cells infected with the purified recombinant virus synthesized influenza hemagglutinin, which was glycosylated and transported to the cell surface where it could be cleaved with trypsin into HA1 and HA2 subunits. Rabbits and hamsters inoculated intradermally with recombinant virus produced circulating antibodies that inhibited hemagglutination by influenza virus. Furthermore, vaccinated hamsters achieved levels of antibody similar to those obtained upon primary infection with influenza virus and were protected against respiratory infection with the A/Jap/305/57 influenza virus.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6580632      PMCID: PMC390012          DOI: 10.1073/pnas.80.23.7155

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

2.  A rapid alkaline extraction procedure for screening recombinant plasmid DNA.

Authors:  H C Birnboim; J Doly
Journal:  Nucleic Acids Res       Date:  1979-11-24       Impact factor: 16.971

3.  In vitro synthesis, glycosylation, and membrane insertion of influenza virus haemagglutinin.

Authors:  K T Elder; J M Bye; J J Skehel; M D Waterfield; A E Smith
Journal:  Virology       Date:  1979-06       Impact factor: 3.616

4.  Nature of Col E 1 plasmid replication in Escherichia coli in the presence of the chloramphenicol.

Authors:  D B Clewell
Journal:  J Bacteriol       Date:  1972-05       Impact factor: 3.490

5.  Complete structure of the hemagglutinin gene from the human influenza A/Victoria/3/75 (H3N2) strain as determined from cloned DNA.

Authors:  W M Jou; M Verhoeyen; R Devos; E Saman; R Fang; D Huylebroeck; W Fiers; G Threlfall; C Barber; N Carey; S Emtage
Journal:  Cell       Date:  1980-03       Impact factor: 41.582

6.  Visualization of an inverted terminal repetition in vaccinia virus DNA.

Authors:  C F Garon; E Barbosa; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

7.  Cloning and DNA sequence of double-stranded copies of haemagglutinin genes from H2 and H3 strains elucidates antigenic shift and drift in human influenza virus.

Authors:  M J Gething; J Bye; J Skehel; M Waterfield
Journal:  Nature       Date:  1980-09-25       Impact factor: 49.962

8.  Cold adapted variants of influenza A. II. Comparison of the genetic and biological properties of ts mutants and recombinants of the cold adapted A/AA/6/60 strain.

Authors:  S B Spring; H F Maassab; A P Kendal; B R Murphy; R M Chanock
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

9.  Identification in a recombinant influenza virus of structural proteins derived from both parents.

Authors:  W G Laver; E D Kilbourne
Journal:  Virology       Date:  1966-11       Impact factor: 3.616

10.  Complete nucleotide sequence of an influenza virus haemagglutinin gene from cloned DNA.

Authors:  A G Porter; C Barber; N H Carey; R A Hallewell; G Threlfall; J S Emtage
Journal:  Nature       Date:  1979-11-29       Impact factor: 49.962

View more
  97 in total

1.  Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta.

Authors:  Jiangao Zhu; Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

2.  Expression of the structural proteins of dengue 2 virus and yellow fever virus by recombinant vaccinia viruses.

Authors:  Y S Hahn; E M Lenches; R Galler; C M Rice; J Dalrymple; J H Strauss
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

3.  Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus.

Authors:  J F Rodriguez; R Janeczko; M Esteban
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

4.  Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells.

Authors:  M Iwashiro; T Kondo; T Shimizu; H Yamagishi; K Takahashi; Y Matsubayashi; T Masuda; A Otaka; N Fujii; A Ishimoto
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

Review 5.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

6.  Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity.

Authors:  C J Langford; S J Edwards; G L Smith; G F Mitchell; B Moss; D J Kemp; R F Anders
Journal:  Mol Cell Biol       Date:  1986-09       Impact factor: 4.272

7.  Genomic characterization of a poxvirus isolated from a child.

Authors:  A Rösen; J Pilaski; G Darai
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

Review 8.  Vaccinia virus: a suitable vehicle for recombinant vaccines?

Authors:  C Kaplan
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

9.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

10.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.

Authors:  S Li; M Rodrigues; D Rodriguez; J R Rodriguez; M Esteban; P Palese; R S Nussenzweig; F Zavala
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.